the Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26/ACTG 5259) M Objective: Compare the effectiveness, tolerability, and safety of 3 months of weekly rifapentine and isoniazid under direct observation (3HP) versus 9 months of daily isoniazid (9H) in HIV-infected persons. Design: Prospective, randomized, and open-label noninferiority trial. Setting: The United States , Brazil, Spain, Peru, Canada, and Hong Kong.
Introduction
The HIV epidemic has worsened tuberculosis control in many countries [1] . HIV infection is the strongest risk factor for progressing from Mycobacterium tuberculosis infection to tuberculosis disease, and globally tuberculosis is the leading cause of death among people with HIV infection [2] [3] [4] [5] [6] . Treatment of M. tuberculosis infection is an important strategy for preventing active tuberculosis and could have a significant impact on decreasing the global tuberculosis burden if implemented broadly [7, 8] . Although treatment of active tuberculosis is highly effective, many patients die without being diagnosed or offered therapy, and transmission of M. tuberculosis to contacts is ongoing from those not on treatment.
Three months of once-weekly rifapentine and isoniazid given under direct observation (3HP) is at least as effective as 9 months of daily self-administered isoniazid (9H) in HIV-uninfected persons [9] and is comparable to isoniazid given for 6 months or continuously in persons with HIV infection [10] . We sought to further evaluate the effectiveness, tolerability, and safety of 3HP in HIV-infected persons by extending enrollment of this patient group in the PREVENT TB trial [9] . The HIV study population has not previously been assessed, and effectiveness, tolerability, and safety endpoints in this population have not previously been reported.
Methods

Study design and patient population
The details of the PREVENT TB trial have been described previously [9] . This was a prospective, openlabel, randomized trial of 3 months of once-weekly rifapentine 600-900 mg (adjusted by weight above or below 50 kg) and isoniazid 15 mg/kg (25 mg/kg in children; rounded up to nearest 50 mg; 900 mg maximum) given under direct observation (3HP) compared with 9 months of daily self-administered isoniazid 5 mg/ kg (15 mg/kg in children, rounded up to nearest 50 mg, 300 mg maximum) (9H). It was recommended that participants receive vitamin B6 50 mg with each dose of isoniazid. HIV testing was recommended, but not required, for enrollment into the PREVENT TB trial.
HIV-infected persons at least 2 years old who were tuberculin skin test positive (!5 mm induration) or who had close contact with a tuberculosis case were eligible for enrollment and were included in this analysis. Participants were enrolled in the United States, Spain, Brazil, Canada, and Hong Kong (all countries with low-to-moderate tuberculosis incidence rates and settings in which treatment of latent M. tuberculosis infection is logistically feasible and a high public health priority) between June 2001 and December 2010. The participants were enrolled from Peru and additional sites in Brazil, between February 2008 and December 2010. The follow-up was through September 2013.
Sample size
We tested the hypothesis that there would be no significant difference in the rates of treatment discontinuation due to adverse drug reaction (ADR) between the two treatment arms. We considered a 5% difference or less in the rates of treatment discontinuation because of ADR to be clinically equivalent. Assuming 15% loss to follow-up, 80% power, type 1 error rate of 0.05, and 1% rate of discontinuation because of ADR in the standard treatment arm, the sample size estimate for testing the main safety hypothesis was 322 persons per arm. However, enrollment was discontinued prior to achieving this sample size because of slow enrollment over the study period.
Randomization
Treatment allocation was based on unrestricted randomization, except in some group settings (e.g. households), in which all participants could be allocated to the same regimen as the first person in the group (cluster); in these situations, only the first person in the group was randomized.
Exclusion criteria included confirmed or suspected tuberculosis, resistance to isoniazid or rifampin in the source case, treatment with a rifamycin or isoniazid during the previous 2 years, sensitivity/intolerance to isoniazid or rifamycins, serum aspartate aminotransferase more than five times the upper limit of normal, pregnancy or breastfeeding, weight less than 10.0 kg, or receiving (or planning to initiate within 90 days of enrollment) HIV-1 protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. The study was approved by the institutional review boards of the Centers for Disease Control and Prevention and all study sites. Written informed consent was obtained from all study participants.
The treatment effectiveness endpoint was cultureconfirmed tuberculosis in persons at least 18 years old and culture-confirmed or clinical tuberculosis in persons less than 18 years old. The secondary effectiveness endpoint was culture-confirmed or clinical tuberculosis regardless of age. All suspected tuberculosis cases were reviewed by an external, blinded three-person expert committee; final diagnoses were by consensus.
Tolerability and safety endpoints included completion of study therapy, permanent discontinuation of therapy, permanent discontinuation for ADR, any grade 3 or 4 drug-related toxicity, all-cause mortality (grade 5 toxicity), and resistance to study medications in M. tuberculosis isolated from study participants who developed tuberculosis. Adverse events were graded by local investigators using common toxicity criteria [11] ; investigators also determined attribution to study drug. The definition of flu-like and other systemic drug reactions is provided in the Supplement (http:// links.lww.com/QAD/A907); this syndrome is described in detail elsewhere [12] .
Trial participants were followed for 33 months from enrollment and evaluated monthly during treatment. Baseline CD4 þ lymphocyte counts were those reported closest to enrollment, from less than 6 months before to 3 months or less after enrollment. Adverse events were reported if they occurred up to 60 days after last dose of study medication. After treatment completion, study visits occurred every 3 months until the 21st month, then at months 27 and 33. Persons lost to follow-up before 33 months were cross-matched with local and state tuberculosis databases. Participants who discontinued study therapy early could be treated with alternative therapy at the discretion of the local investigator, and the follow-up continued.
Quality assurance
Quality assurance was ensured at all study sites through adherence to a common study protocol, standardized training of study investigators and study coordinators, external monitoring performed at least annually (by Westat), and quality assurance review of data by the study data center at the Centers for Disease Control and Prevention.
Statistical analysis
We sought to assess whether 3HP was noninferior to 9H. Without treatment, tuberculosis risk in persons with HIV and M. tuberculosis coinfection is estimated to be 5% annually [3] . Overall, 12 months of isoniazid is 55-83% effective in the general population; 68% has been estimated for a 9-12-month course [13] . In persons with HIV infection, treatment of M. tuberculosis infection is 11-62% effective, depending on the tuberculin skin test result [14] . Assuming a conservative estimate of 68% effectiveness, there would be (1.0-0.68) Â 5% ¼ 1.6% tuberculosis cases annually in the 9H arm. We defined noninferiority as 17% of the expected case rate in the 9H arm (17% Â 1.6% Â 2.75 years ¼ 0.75%) in 33 months (2.75 years), which corresponds to an absolute noninferiority margin (delta) of 0.75%. This margin was selected for the end of follow-up (33 months) [9] . See the Supplement for a detailed justification of the noninferiority margin (http://links.lww.com/QAD/A907).
The analysis groups were defined as follows: modified intention-to-treat (MITT) included all persons enrolled who were eligible. The per-protocol population included all eligible persons enrolled who completed the assigned study regimen (defined as at least 11 of 12HP doses within 16 weeks or at least 240 of 270H doses within 52 weeks), or persons who developed tuberculosis or died but completed at least 75% of the expected number of doses prior to the event. Tuberculosis rates were assessed 33 months after enrollment. In the MITT and per-protocol population analysis, all follow-up time contributed was included. The MITT population, followed up to 33 months from enrollment, was considered the primary analysis population for effectiveness. The per-protocol population was used to evaluate efficacy. The safety analysis was performed among all persons who received at least one dose of study drug. The 95% confidence interval (CI) of the difference of the rates of discontinuation because of ADR was calculated and then compared with the equivalence range (À5 to 5%). P values were calculated with Fisher's exact test to determine whether the rates were significantly different. Analyses were also performed with participants from one study site (Site A; n ¼ 70) excluded because of possible discrepancies at that site regarding receipt of study drug and directly observed therapy. See Supplement Table 1 , http://links.lww.com/QAD/ A907, for the study populations.
A Cox regression analysis was performed to assess demographic and clinical risk factors for tuberculosis. The proportional hazards assumption was verified by plotting the negative log of the survivor functions versus the log of time, and for suspect factors, an interaction with time was analyzed. Participants who initiated antiretroviral therapy during the study did so at different times. Antiretroviral therapy was therefore examined as a timedependent variable, with the initiation of antiretroviral therapy being measured from enrollment date. For all analyses, statistical significance was achieved with a P value less than 0.05, unless stated otherwise. 
Enrollment began in
Results
There were 403 persons with HIVenrolled in the study, of whom four were subsequently found to be ineligible (see Supplement Table 2 , http://links.lww.com/QAD/ A907). Therefore, 399 persons were included in the MITT study population: 206 in the 3HP arm and 193 in the 9H arm. The clinical and demographic characteristics of the MITT study population are shown in Table 1 . There were no statistically significant differences by study arm in median age, sex, race, region of enrollment, history of alcohol, injection drug, or tobacco use, hepatitis C virus infection, BMI, or median baseline CD4 þ lymphocyte count. The numbers (%) of participants with more than 350 CD4 þ lymphocytes/ml were 158 (84%) and 140 (84%) in the 3HP and 9H arms, respectively. There was no significant difference in the cumulative loss to follow-up rate by treatment arm (log-rank P ¼ 0.34), and fewer than 16% of enrolled participants from either arm were lost through day 800 after enrollment (Supplement Figure 2 , http:// links.lww.com/QAD/A907). There were 67 participants (33%) in the 3HP arm and 58 (30%) in the 9H arm who received antiretroviral therapy during the study (P ¼ 0.67) at a median time after enrollment of 284 days (IQR 179-544) in the 3HP arm versus 186 days (IQR 89-392) in the 9H arm (P ¼ 0.06). Of the 403 persons enrolled, five were children less than 18 years old, and all were at least 12 years old.
In the MITT population, two tuberculosis episodes occurred during 517 person-years (p-y) of follow-up in the 3HP arm (0.39 episodes per 100 p-y) and six tuberculosis episodes during 481 p-y of follow-up in the 9H arm (1.25 episodes per 100 p-y) ( Fig. 1 and Table 2 ). Cumulative tuberculosis rates were 1.01 versus 3.50% in the 3HP and 9H arms, respectively (difference in cumulative tuberculosis rate: À2.49%; upper bound of 1610 AIDS 2016, Vol 30 No 10 Of the eight tuberculosis cases, three received antiretroviral therapy prior to developing active tuberculosis. All three participants were in the 9H arm, and the times from antiretroviral therapy initiation to tuberculosis diagnosis were 143, 181, and 221 days.
Among those participants with CD4 þ lymphocyte counts at study entry, the median CD4 þ cell count was 366 (IQR 338-460; n ¼ 6) in those who developed tuberculosis versus 513 (IQR 404-710; n ¼ 348) in those who did not (P ¼ 0.1). Of the eight tuberculosis cases, resistance testing was performed on all: six had no resistance to firstline antituberculosis drugs, one isolate identified as Mycobacterium bovis had resistance to rifampin and pyrazinamide (3HP arm; participant enrolled in the United States), and one isolate had resistance to isoniazid, rifampin, and streptomycin (9H arm; participant enrolled in Peru).
Treatment completion was significantly higher in the 3HP arm than the 9H arm (Table 3 ). Treatment discontinuation because of ADR was similar in both study arms, and the 95% CI of the difference was À4.7 to 2.9, which was within the equivalence range of À5 to 5% ( Table 3 ). Rates of drug discontinuation because of grade 3 or higher ADR s were low and similar in the two arms. Drug discontinuation because of hepatotoxicity was significantly higher in the 9H arm (4%) than the 3HP arm (1%; P ¼ 0.05). Flu-like/systemic drug reactions occurred in two patients in the 3HP arm and none in Table 4 , http://links.lww.com/ QAD/A907).
Treatment effectiveness was compared among HIVinfected participants to the HIV-uninfected participants in the PREVENT TB study (Supplement Table 5 , http://links.lww.com/QAD/A907). In the MITT population, the difference in cumulative tuberculosis rate between HIV-infected and HIV-uninfected persons who received 3HP was 0.83%. As the CI of the difference contained zero, there was no statistical evidence that the 3HP tuberculosis rates differed by HIV status. The difference in cumulative tuberculosis rate by HIV status in the 9H arm was 2.97%. The cumulative tuberculosis rate among HIV-infected participants was significantly higher than the rate among HIV-uninfected participants (3.50 vs. 0.53%; P ¼ 0.018).
The tolerability of the two regimens in HIV-infected versus HIV-uninfected participants is summarized in Supplement Table 6 , http://links.lww.com/QAD/A907. In the 3HP arm, rates of treatment completion were higher (88.8 vs. 80.2%; P ¼ 0.002), and rates of flu-like/ systemic drug reactions were lower (1.0 vs. 4.6%; P ¼ 0.01) among HIV-infected persons. In the 9H arm, rates of grade 3 and 4 toxicity, hepatotoxicity, and serious adverse events were higher in HIV-infected than HIV-uninfected persons. In both study arms, the risk of death was higher in HIV-infected than HIV-uninfected persons, though it was not statistically significant in the 9H arm.
The univariate and multivariate analyses for risk factors associated with developing tuberculosis are described in Supplement Table 8 , http://links.lww.com/QAD/A907. All factors were independently examined and met the proportional hazard assumption. Factors independently associated with tuberculosis risk were baseline CD4 þ lymphocyte count less than 350 cells/ml and low BMI.
There were no statistically significant 2-by-2 interaction terms among these factors, nor any interactions of them with treatment regimen. After adjusting for these variables, participants randomized to 3HP were less likely to progress to tuberculosis compared with participants randomized to 9H, but the difference was not statistically significant (adjusted HR, 0.27; 95% CI, 0.05-1.44; P ¼ 0.13).
Discussion
In the primary effectiveness population (MITT), 3HP was noninferior to 9H for treatment of M. tuberculosis infection in persons with HIV infection. In addition, the 3HP regimen had a higher treatment completion rate and was as well tolerated as 9H, with similar rates of grade 3, 4, and 5 toxicity in the two arms. Compared with 9H, the 3HP regimen had a significantly lower rate of drug discontinuation because of hepatotoxicity, and the risk of flu-like and other systemic drug reactions was also low. Although noninferiority was not achieved in the per-protocol population analysis (likely due to the low number of events), the per-protocol population results were consistent with the MITT results, as well as with previous findings in the PREVENT TB trial, and with a study among persons with HIV infection in South Africa [9, 10] . Taken together, these clinical trials demonstrate that 3HP is effective and well tolerated to treat latent M. tuberculosis infection in persons with HIV infection and high CD4 þ lymphocyte counts (median CD4 þ cell count in this study approximately 500 cells/ml) who have not started antiretroviral therapy.
Study recruitment was limited to persons who did not plan to receive antiretroviral therapy within 90 days of enrollment because at the time the study was designed, there were no data on the drug interactions between rifapentine and HIV-1 protease inhibitors or nonnucleoside reverse transcriptase inhibitors. However, recent studies have demonstrated that rifapentine, given either once weekly or daily, has minimal interaction with daily efavirenz [15, 16] . Furthermore, additional studies have demonstrated that once-weekly rifapentine may be given with the integrase strand transfer inhibitor raltegravir [17] . Although studies of the effectiveness of 3HP when given with efavirenz or raltegravir-based antiretroviral therapy are needed, these pharmacokinetic studies suggest that such regimens can be given concomitantly. Such effectiveness studies would likely include persons with lower CD4 þ lymphocyte counts.
The requirement that participants not receive antiretroviral therapy for at least 90 days after enrollment likely contributed to the slow enrollment. Because of the slow pace, it was decided to stop enrollment before reaching the target sample size.
There were different numbers of participants in each study arm. This could be because of minor imbalances related to unrestricted randomization. In addition, study participants living in the same household received the same treatment as the first person in the household. Thus, only the first person in the household was randomized, and there were differences by regimen in the number of persons in households. Early in the study, household members did not have to provide informed consent before the first member was randomized, and this may have influenced participation by arm.
The multivariate risk factor analysis identified several factors that were independently associated with tuberculosis risk, including baseline CD4 þ lymphocyte count less than 350 cells/ml. This is consistent with prior studies demonstrating the strong association between low CD4 þ lymphocyte count and tuberculosis risk [18, 19] . Antiretroviral therapy decreases tuberculosis risk independent of treatment of latent M. tuberculosis infection with daily isoniazid, presumably because of both increases in CD4 þ lymphocyte count and decline in HIV-1 RNA [20] [21] [22] [23] [24] . In this study, approximately 30% of the participants received antiretroviral therapy during the study period, but the risk factor analysis did not find antiretroviral therapy to be significantly associated with tuberculosis risk (Supplement Table 8 , http://links.lww.com/QAD/A907). We did not have information on the number of participants who achieved virologic suppression. To accurately assess the role of changes in CD4 þ lymphocyte count on tuberculosis risk, repeated measures of this time-varying variable would be needed, which was not available in this study. In addition, antiretroviral therapy use was not randomized, so the analysis of time-dependent antiretroviral therapy is subject to indication bias.
Low baseline BMI was also independently associated with tuberculosis risk. Although it has been known that low BMI is associated with increased tuberculosis risk [24] [25] [26] , it is unclear whether interventions specifically to increase BMI during treatment of latent M. tuberculosis infection further decrease the risk compared with medication alone; antiretroviral therapy is also associated with weight gain.
In this study, active tuberculosis at baseline was excluded by clinical evaluation and chest radiograph. HIV-infected persons with active tuberculosis who receive onceweekly rifapentine and isoniazid in the continuation phase of treatment are at increased risk of acquired rifamycin resistance [27] . Although there is no evidence that treatment of latent M. tuberculosis infection in persons with HIV infection leads to development of drugresistant tuberculosis, ruling out disease prior to starting preventive therapy is important. In the study of 3HP in Soweto, South Africa, a setting with high rates of tuberculosis and multidrug-resistant tuberculosis, there was no clear evidence that preventive treatment selected for resistance [10] . In this study, two of the eight tuberculosis cases had rifampin resistance, but one occurred in the 9H arm, in a participant from Peru, who has high background rates of drug resistance. The second case was because of M. bovis, which was resistant to pyrazinamide as expected, and rifampin. Given the low number of tuberculosis cases in these studies, development of resistance will be important to assess as the 3HP regimen is used more widely. Although there were possible discrepancies at Site A regarding receipt of study drug and directly observed therapy, participants from this site were retained in the primary analyses because they met the criteria of the MITT study population (i.e. eligible for the study and randomized). All randomized participants should be included in intention-to-treat analyses [28, 29] . However, additional analyses with these participants removed did not change the direction of the associations for effectiveness, efficacy, or safety, though the CIs were wider because of the smaller sample size (Supplement Table 7 and Figure 4 , http://links.lww.com/QAD/ A907).
In the comparison between HIV-infected persons in this
There were several limitations of this study. First, the sample size was small. However, there was sufficient statistical power to demonstrate that 3HP was as well tolerated as 9H, based on the criteria that were established before the study started (equivalence region of À5 to 5% for the difference in drug discontinuation because of ADR). In addition, the number of tuberculosis cases was sufficiently high to be able to establish noninferiority of 3HP in the MITT analysis. Second, there were few children enrolled. Children were retained in the analysis as we are unaware of substantial differences in M. tuberculosis pathogenesis in HIVinfected children compared with adults. Although a recent analysis of predominantly HIV-uninfected children demonstrated good safety and effectiveness of 3HP [30] , additional data are needed in HIV-infected children. Third, the study had an open-label design, with both participants and clinicians aware of the regimen received. There were also differences in dosing frequency and duration between the two study arms. The higher treatment completion rates in the 3HP arm were likely because of both direct observation and the shorter treatment course.
Our study indicates that 3HP is as effective as 9H for the treatment of latent M. tuberculosis infection in HIVinfected persons with high CD4 þ lymphocyte counts (median approximately 500 cells/ml) who have not initiated antiretroviral therapy. 3HP is safe, well tolerated, and associated with higher treatment completion rates than 9H; this regimen should be used for treatment of latent M. tuberculosis infection in appropriately selected persons with HIV. Further studies of 3HP in advanced HIV disease, including those with concurrent antiretroviral therapy, are needed.
For study sites and personnel, please see the Supplement (http://links.lww.com/QAD/A907).
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